Alagille综合征患儿临床治疗管理

doi:10.3969/j.issn.1672-5069.2021.02.003

Abstract

Guo Li, Song Yuanzong. Clinical management of pediatric patients with Alagille syndrome[J]. Journal of Practical Hepatology, 2021, 24(2): 160-163.

[1] 马艳立,宋元宗. Alagille综合征诊断治疗进展. 中国当代儿科杂志,2014, 16(11):1188-1192.
[2] Binita MK, Kathleen ML, David AP. Medical management of Alagille syndrome.J Pediatr Gastroenterol Nutr, 2010, 50(6):580-586.
[3] EDNel, AJ Terblanche. Nutritional support of children with chronic liver disease. S Afr Med J, 2015, 105(7):607.
[4] Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol, 2011, 35(2):89-97.
[5] Narkewicz MR, Smith D, Gregory C, et al. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr, 1998, 26(1):49-55.
[6] Mela M, Mancuso A, Burroughs AK. Pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther, 2003, 17(7):857-870.
[7] Hofmann AF.Rifampicin and treatment of cholestatic pruritus. Gut, 2002, 51(5): 756-757.
[8] Kronsten V, Fitzpatrick E, Baker A. Management of cholestatic pruritus in pediatric patients with Alagille syndrome: the King’s College Hospital experience. J Pediatr Gastroenterol Nutr, 2013, 57(2):149-154.
[9] Zellos A, Roy A, Schwarz KB. Use of oral naltrexone for severe pruritus due to cholestatic liver disease in children. J Pediatr Gastroenterol Nutr, 2010, 51(6):787-789.
[10] S Ben Ameur, I Chabchoub, J Telmoudi, et al. Management of cholestatic pruritus in children with Alagille syndrome: Case report and literature review. Arch Pediatr, 2016, 23(12):1247-1250.
[11] Ayoub MD, Kamath BM. Alagille syndrome: Diagnostic challenges and advances in management. Diagnostics (Basel), 2020, 10(11):907.
[12] Schwartz R, Rehder K, Parsons DJ, et al. Intense pruritus and failure to thrive in Alagille syndrome. J Am Acad Dermatol, 2008, 58(2 Suppl):S9-11.
[13] Alves C, Braid Z. Homozygous familial hypercholesterolemia: case report of a rare cause of dyslipidemia. Pediatr Endocrinol Diabetes Metab, 2011, 17(3):162-165.
[14] Constantin AT. Statins treatment and oro-dental aspects in a case of hereditary hypercholesterolemia in a child under 6 years. Acta Endocrinol (Buchar), 2019, 15(3):378-383.
[15] Sullivan DR, Hamilton-Craig I, van Bockxmeer F, et al. INTERIM guidelines for the diagnosis and management of familial hypercholesterolaemia. Heart Lung Circ, 2012, 21(3):159-162.
[16] Flores CD , Yu YR , Miloh TA , et al. Surgical outcomes in Alagille syndrome and PFIC: A single institution's 20-year experience. J Pediatr Surg, 2018, 53(5):976-979.
[17] Wang KS, Tiao G, Bass LM, et al. Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis. Hepatology, 2017, 65(5):1645-1654.
[18] Ramachandran P , Shanmugam N P , Sinani S A , et al. Outcome of partial internal biliary diversion for intractable pruritus in children with cholestatic liver disease. Pediat Surg Int, 2014, 30(10):1045-1049.
[19] Emerick KM, Rand EB, Goldmuntz E, et al. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology, 1999, 29(3):822-829.
[20] Hoffenberg EJ, Narkewicz MR, Sondheimer JM, et al. Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy. J Pediatr, 1995, 127(2):220-224.
[21] Lykavieris P, Hadchouel M, Chardot C, et al. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut, 2001, 49(3):431-435.
[22] Quiros-Tejeira RE, Ament ME, Heyman MB, et al. Variable morbidity in Alagille syndrome: a review of 43 cases. J Pediatr Gastroenterol Nutr, 1999, 29(4):431-437.
[23] Kamath BM, Podkameni G, Hutchinson AL, et al. Renal anomalies in Alagille syndrome: A disease-defining feature. Am J Med Genet A, 2012,158A(1):85-89.
[24] 沈丛欢, 马恩斯, 陶一峰,等. 儿童肝移植治疗Alagille综合征的疗效分析. 中华移植杂志(电子版), 2020,14(1):34-37.
[25] McElhinney DB, Krantz ID, Bason L, et al. Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation, 2002, 106(20):2567-2574.
[26] Saidi AS, Kovalchin JP, Fisher DJ, et al. Balloon pulmonary valvuloplasty and stent implantation. For peripheral pulmonary artery stenosis in Alagille syndrome. Tex Heart Inst J, 1998, 25(1):79-82.
[27] Emily Ruckdeschel, Yuli Y Kim. Pulmonary valve stenosis in the adult patient: pathophysiology, diagnosis and management. Heart, 2019, 105(5):414-422.
[28] Cuypers JAAE, Witsenburg M, van der Linde D, et al. Pulmonary stenosis: update on diagnosis and therapeutic options. Heart, 2013, 99(5):339-347.
[29] Gandhi SK, Reyes J, Webber SA, et al. Case report of combined pediatric heart-lung-liver transplantation. Transplantation, 2002, 73(12):1968-1969.
[30] Di Pinto D, Adragna M. Renal manifestations in children with Alagille syndrome. Arch Argent Pediatr, 2018, 116(2):149-153.
[31] Lennert T, Tetzner M, Er M, et al. Multicystic renal dysplasia: nephrectomy versus conservative treatment. Contrib Nephrol, 1988, 67:183-187.
[32] Chen RY, Chang H. Renal dysplasia. Arch Pathol Lab Med, 2015, 139(4):547-551.
[33] Neild GH, Thomson G, Nitsch D, et al. Renal outcome in adults with renal insufficiency and irregular asymmetric kidneys. BMC Nephrol, 2004, 5:12.
[34] Bagga A, Sinha A. Renal tubular acidosis. Indian J Pediatr, 2020, 87(9):733-744.
[35] Hingorani M, Nischal KK, Davies A, et al. Ocular abnormalities in Alagille syndrome. Ophthalmology, 1999,106(2):330-337.
[36] Nischal KK , Hingorani M , Bentley CR , et al. Ocular ultrasound in Alagille syndrome: a new sign. Ophthalmology, 1997, 104(1):79.
[37] Chang MY, Pineles SL. Optic disc drusen in children. Surv Ophthalmol, 2016, 61(6):745-758.
[38] Wagley Y, Mitchell T, Ashley J, et al. Skeletal involvement in Alagille syndrome. In Alagille Syndrome. Springer: Cham, Switzerland, 2018:121-136.

Clinical management of pediatric patients with Alagille syndrome

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yuan Pingge, Chen Wenwen. Insights to new medicine development for treatment of patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 305-307.
[2]	Xu Wenting, Zhang Jihong, Wei Dongjue, et al. Efficacy of tenofovir rescue therapy for patients with chronic hepatitis B and rtM204 mutation [J]. Journal of Practical Hepatology, 2021, 24(3): 335-338.
[3]	Wang Xue, Qu Falin, Qi Weili, et al. Balance of peripheral blood Treg cells/ Th17 cells in patients with chronic hepatitis B and its impact on response to telbivudine treatment [J]. Journal of Practical Hepatology, 2021, 24(3): 339-342.
[4]	Qi Mei, Zhang Ruijin, Tian Shuping, et al. Impacting factors in response to immunosuppressive therapy in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 371-374.
[5]	Wang Yunqiang, Wang Liping, Huang Dongmei, et al. Changes ofportal hemodynamics in patients with hepatitis B cirrhosis after transjugular intrahepatic portosystemic stent-shunt [J]. Journal of Practical Hepatology, 2021, 24(3): 399-402.
[6]	Wu Chang, Zhang Yuan’an, Peng Chunfen. Efficacy of endoscopic variceal ligation and carvedilol maintenance in the treatment of patients with liver cirrhosis and esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2021, 24(3): 403-406.
[7]	Zhao Kai, Xue Jinfeng, Xue Pengfei, et al. Application of Viatorr covered stent in TIPS for treatment of cirrhotics with portal hypertension [J]. Journal of Practical Hepatology, 2021, 24(3): 419-422.
[8]	Feng Hao, Lyu Haitao, Wang Ziwei, et al. Efficacy of one-step and step-by-steplaparoscopic cholecystectomy in the treatment of patients with gallbladder stones and common bile duct stones [J]. Journal of Practical Hepatology, 2021, 24(3): 435-438.
[9]	Zhang Xinhe, Tian Haoyu, Li Yiling. Current therapeutic strategy for patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2021, 24(3): 453-456.
[10]	He Yufeng, Zhong Xiaoni, Huang Jianrong, et al. Short-term efficacy of tenofovir dipivoxil and entecavir in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(2): 200-203.
[11]	Nie Liu, Peng Hanming, Liao Dongliang. Combination of ursodeoxycholic acid and prednisone and azathioprine in the treatment of patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(2): 224-227.
[12]	Liu Yunhua, Da Rongfeng, Xu Hubo, et al. Therapeutic efficacy of polyene phosphatidylcholine in patients with anti-tuberculosis agents-induced liver injury [J]. Journal of Practical Hepatology, 2021, 24(2): 228-231.
[13]	Lin Cheng, Wang Tongbiao, Li Yueyong, et al. Short-term efficacy of magnesium isoglycyrrhizinate and adenosylmethionine butanedisulfonate combination in treatment of patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2021, 24(2): 232-235.
[14]	Zhang Yan, Xia Wenfang, Jin Jin, et al. Short-term observation ofglicladine and insulin aspart 50 in the treatment of patients with non-alcoholic fatty liver diseases and hepatogenic diabetes [J]. Journal of Practical Hepatology, 2021, 24(2): 240-243.
[15]	Li Man, Li Jing, Chen Wenling, et al. Clinical observation of external local high frequency thermotherapy and radiotherapy in the treatment of patients with advanced hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(2): 256-259.